You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: AMU begins Covaxin phase-3 trials, VC registers as 1st volunteer

Principal Investigator Prof Mohammad Shameem said ICMR Covaxin Phase 3 trial is going on after the Phase 1 and Phase 2 trials showed encouraging results

Coronavirus | Aligarh Muslim University | Coronavirus Vaccine

Press Trust of India  |  Lucknow 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma

As the trial of COVID-19 vaccine enters the third phase, AMU Vice Chancellor Professor Tariq Mansoor on Tuesday got himself registered to be the first volunteer for the Covaxin trials.

The phase 3 trials of Covaxin developed by Bharat Biotech began at JN Medical College and Hospital (JNMCH) of the (AMU) here.

Prof Tariq Mansoor volunteered himself to motivate and inspire others to come forward, an AMU spokesman said.

Covaxin Phase 3 trial is aimed at evaluating the safety and efficacy of the vaccine study led in collaboration with the Indian Council of Medical Research (ICMR) and Bharat Biotech, he said.

Seeking active participation from all age groups and socio-economic background in the clinical trials, the AMU VC said, "By volunteering for a trial or study, one get a chance to participate in ground breaking research and contribute to developing better cure and treatment options."

JNMCH principal Prof Shahid Ali Siddiqui said an ethical committee comprising doctors, social workers and lawyers, has already been constituted to manage the clinical trials. He said the required staff for conducting the vaccine trial has been recruited and the registration of volunteers has also been started from Tuesday.

Principal Investigator Prof Mohammad Shameem said ICMR Covaxin Phase 3 trial is going on after the Phase 1 and Phase 2 trials showed encouraging results.

Volunteers who will undergo the Phase 3 trial will receive travel expenses and other benefits as per ICMR guideline, AMU spokesman said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 10 2020. 22:09 IST